Beckley psychedelic hits the target, unlocking atai merger The proposed merger between Beckley Psytech and atai is unlocked as a psychedelic for depression hits all its endpoints in a phase 2b trial.

UK #psychedelicmedicines developer #BeckleyPsytech is preparing to take its psychedelic medicine for severe #depression into a pivotal trials programme on the back of a positive phase 2b readout.

Beckley Psytech announces positive results for ELE-101 in depression trial - PharmaTimes Phase 2a study shows promising antidepressant effects

#depression #mentalhealth #drugdevelopment #antidepressant #MajorDepressiveDisorder #MDD #BeckleyPsytech #psychedelics #licensedmedicines #ELE101 #clinicaltrial #Phase2astudy #IVformulation #psilocinbenzoate #MDDpatients #MADRSscores #rapidactingMDDtreatment
pharmatimes.com/news/beckley...